Abstract: Drug-resistant bacteria have been on the offensive for years, with few new compounds available for a counterattack. But at a recent meeting, pharmaceutical companies introduced a promising crop of new antibiotics, with a variety of ways to beat back resistance. Whether companies have enough incentives to develop the most effective anti-resistance strategies—narrow-spectrum antibiotics—remains an open question. See sidebar (p. 725).
Publication Year: 1995
Publication Date: 1995-11-03
Language: en
Type: article
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 137
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot